Centaurus Financial’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.18M | Buy |
19,494
+9,516
| +95% | +$555K | 0.06% | 303 |
|
|
2025
Q4 | $538K | Sell |
9,978
-605
| -6% | -$29.1K | 0.02% | 517 |
|
|
2025
Q3 | $477K | Sell |
10,583
-1,588
| -13% | -$74.2K | 0.02% | 540 |
|
|
2025
Q2 | $563K | Buy |
12,171
+49
| +0.4% | +$2.4K | 0.03% | 439 |
|
|
2025
Q1 | $739K | Sell |
12,122
-53
| -0.4% | -$3.09K | 0.04% | 347 |
|
|
2024
Q4 | $689K | Buy |
12,175
+1,256
| +12% | +$70.2K | 0.04% | 352 |
|
|
2024
Q3 | $565K | Buy |
10,919
+1,920
| +21% | +$90.1K | 0.04% | 389 |
|
|
2024
Q2 | $374K | Sell |
8,999
-1,837
| -17% | -$82.2K | 0.02% | 448 |
|
|
2024
Q1 | $588K | Sell |
10,836
-1,188
| -10% | -$60.5K | 0.04% | 354 |
|
|
2023
Q4 | $617K | Sell |
12,024
-605
| -5% | -$31.8K | 0.05% | 321 |
|
|
2023
Q3 | $733K | Buy |
12,629
+24
| +0.2% | +$1.47K | 0.06% | 287 |
|
|
2023
Q2 | $806K | Sell |
12,605
-5,857
| -32% | -$393K | 0.07% | 273 |
|
|
2023
Q1 | $1.28M | Buy |
18,462
+816
| +5% | +$57.6K | 0.1% | 222 |
|
|
2022
Q4 | $1.27M | Buy |
17,646
+98
| +0.6% | +$7.39K | 0.12% | 196 |
|
|
2022
Q3 | $1.25M | Sell |
17,548
-52
| -0.3% | -$3.77K | 0.12% | 199 |
|
|
2022
Q2 | $1.35M | Sell |
17,600
-2,787
| -14% | -$212K | 0.13% | 188 |
|
|
2022
Q1 | $1.49M | Sell |
20,387
-2,791
| -12% | -$187K | 0.12% | 210 |
|
|
2021
Q4 | $1.45M | Buy |
23,178
+1,052
| +5% | +$61.7K | 0.11% | 212 |
|
|
2021
Q3 | $1.31M | Buy |
22,126
+990
| +5% | +$65.2K | 0.11% | 220 |
|
|
2021
Q2 | $1.41M | Buy |
21,136
+2,078
| +11% | +$135K | 0.12% | 208 |
|
|
2021
Q1 | $1.2M | Sell |
19,058
-8,063
| -30% | -$502K | 0.12% | 210 |
|
|
2020
Q4 | $1.68M | Buy |
27,121
+811
| +3% | +$49.9K | 0.18% | 143 |
|
|
2020
Q3 | $1.59M | Sell |
26,310
-20,292
| -44% | -$1.22M | 0.22% | 107 |
|
|
2020
Q2 | $2.74M | Buy |
46,602
+13,970
| +43% | +$836K | 0.41% | 54 |
|
|
2020
Q1 | $1.82M | Sell |
32,632
-596
| -2% | -$36.4K | 0.36% | 73 |
|
|
2019
Q4 | $2.13M | Buy |
33,228
+11,437
| +52% | +$655K | 0.3% | 79 |
|
|
2019
Q3 | $1.1M | Buy |
21,791
+628
| +3% | +$29.5K | 0.17% | 144 |
|
|
2019
Q2 | $960K | Buy |
21,163
+20,386
| +2,624% | +$950K | 0.15% | 164 |
|
|
2019
Q1 | $16.3K | Buy |
777
+177
| +30% | +$8.82K | 0.1% | 185 |
|
|
2018
Q4 | $12 | Buy |
600
+590
| +5,900% | +$31.7K | 0.09% | 173 |
|
|
2018
Q3 | $595 | Sell |
10
-18,313
| -100% | -$1.09M | 0.11% | 219 |
|
|
2018
Q2 | $1.01M | Buy |
18,323
+13,228
| +260% | +$714K | 0.14% | 165 |
|
|
2018
Q1 | $322K | Buy |
5,095
+221
| +5% | +$14.2K | 0.08% | 253 |
|
|
2017
Q4 | $299K | Buy |
+4,874
| New | +$305K | 0.08% | 243 |
|
Other funds holding BMY
VCM
VPM
Centaurus Financial's BMY Position: Q1 2026 in Review
Centaurus Financial increased its Bristol-Myers Squibb (BMY) stake by 95% in Q1 2026, buying an estimated $555K and bringing the position to 19,494 shares worth $1.18M. The position accounts for 0.06% of the portfolio, ranked #303.
Centaurus Financial first reported a position in BMY in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.74M in Q2 2020. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Centaurus Financial held 19,494 shares of Bristol-Myers Squibb worth $1.18M as of Q1 2026.
- Centaurus Financial bought 9,516 Bristol-Myers Squibb shares in Q1 2026, an estimated $555K.
- Bristol-Myers Squibb made up 0.06% of Centaurus Financial's portfolio in Q1 2026, its #303 holding.
- Centaurus Financial first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 34 quarters since.
- Centaurus Financial's Bristol-Myers Squibb position peaked at $2.74M in Q2 2020.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Centaurus Financial's 13F filing for Q1 2026, filed 18 May 2026.